(Q41338162)

29 September 2017

Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients (English)

1 reference

29 September 2017

1 reference

1 reference

Min Zhu

1

1 reference

29 September 2017

Marc Bifano

2

1 reference

29 September 2017

Xu Xu

3

1 reference

29 September 2017

Yonghua Wang

4

1 reference

29 September 2017

Frank LaCreta

5

1 reference

29 September 2017

Dennis Grasela

6

1 reference

29 September 2017

Marc Pfister

7

1 reference

29 September 2017

language of work or name

English

0 references

publication date

7 April 2008

1 reference

29 September 2017

6

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

29 September 2017

52

1 reference

29 September 2017

8

1 reference

29 September 2017

2836-2841

1 reference

The HBV drug entecavir - effects on HIV-1 replication and resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

The pathology of malabsorption: current concepts

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Entecavir: a review of its use in chronic hepatitis B.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Optimizing management strategies in special patient populations

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Progress on the control of hepatitis B infection through immunisation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Prediction of creatinine clearance from serum creatinine

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Hepatitis B virus infection in the acquired immunodeficiency syndrome

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

11 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2493122

Management of chronic hepatitis B and C in HIV-coinfected patients

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18391039

12 December 2020

inferred from PubMed ID database lookup

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18391039

12 December 2020

inferred from PubMed ID database lookup

Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18391039

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1128/AAC.01366-07

1 reference

29 September 2017

1 reference

29 September 2017

PubMed publication ID

18391039

1 reference